- 专利标题： Human plasma kallikrein inhibitors
-
申请号： US15764071申请日： 2016-09-30
-
公开(公告)号： US10562850B2公开(公告)日： 2020-02-18
- 发明人: Pravin L. Kotian , Yarlagadda S. Babu , V. Satish Kumar , Weihe Zhang , Lakshminarayana Vogeti
- 申请人： BioCryst Pharmaceuticals, Inc.
- 申请人地址： US NC Durham
- 专利权人： BioCryst Pharmaceuticals, Inc.
- 当前专利权人： BioCryst Pharmaceuticals, Inc.
- 当前专利权人地址： US NC Durham
- 代理机构： Foley Hoag LLP
- 代理商 Dana M. Gordon
- 国际申请： PCT/US2016/054619 WO 20160930
- 国际公布： WO2017/059178 WO 20170406
- 主分类号： C07D401/14
- IPC分类号： C07D401/14 ; C07D207/12 ; A61K31/444 ; A61K31/40 ; C07D207/16 ; C07D401/12 ; C07D409/14 ; C07D207/24 ; A61P17/00
摘要：
Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
公开/授权文献
- US20180362458A1 HUMAN PLASMA KALLIKREIN INHIBITORS 公开/授权日：2018-12-20
信息查询
